Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Edoxaban Tosylate,Warfarin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2024
Lead Product(s) : Edoxaban Tosylate,Warfarin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edoxaban Tosylate,Tegoprazan,Apixaban,Rivaroxaban
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : Edoxaban Tosylate,Tegoprazan,Apixaban,Rivaroxaban
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2022
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apixaban,Dabigatran Etexilate Mesylate,Edoxaban Tosylate,Rivaroxaban
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Apixaban,Dabigatran Etexilate Mesylate,Edoxaban Tosylate,Rivaroxaban
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dabigatran Etexilate Mesylate,Rivaroxaban,Apixaban,Edoxaban Tosylate
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Dabigatran Etexilate Mesylate,Rivaroxaban,Apixaban,Edoxaban Tosylate
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from the ETNA-AF-Europe Registry provide information on edoxaban in routine clinical practice in subpopulations that include frail patients and those with worsening renal function.
Product Name : Lixiana
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2021
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48.
Product Name : Lixiana
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2021
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edoxaban Tosylate,Potassium Warfarin
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 29, 2021
Lead Product(s) : Edoxaban Tosylate,Potassium Warfarin
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This application is based on results from the Japanese phase 3 clinical trial (ELDERCARE-AF Study) in 984 non-valvular atrial fibrillation patients of 80 years and above with a high bleeding risk and who are ineligible for other available anticoagulation...
Product Name : Lixiana
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2020
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary endpoint has been achieved in the Japan phase 3 clinical trial (ELDERCARE AF Study; hereinafter, the study) for the anticoagulant, edoxaban, in elderly patients with non-valvular atrial fibrillation and high bleeding risk.
Product Name : Lixiana
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Edoxaban Tosylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable